No. DOD-E067/2565
July 18th, 2022
Subject: Use of proceeds from initial public offering of ordinary shares
To: President
The Stock Exchange of Thailand
DOD Biotech Public Company Limited ("the Company") made an initial public offering ("IPO") of ordinary shares during June 12-14, 2018 in the amount of 110,000,000 shares each of Baht0.50 par value at the offering price of Baht 9.30 per share, totaling Baht 1,023,000,000. After deduction of offering expenses, the proceeds from the IPO amount to Baht 987,240,850.
The company would link to report the use of capital increase from the IPO for January 1, 2022 to June 30, 2022 as follows:
Purposes of use | Amount | Resolution of | Resolution of | Amount | Accumulated | Balance | |||||||||||||||||
(Unit: Baht million) | earmarked | the Board of | the 2019 | used during | amount used | remaining | |||||||||||||||||
Directors No. | Annual | period | (Jun 15, 2018- | (Jun 30, | |||||||||||||||||||
8/2018 on | General | (Jan 1, 2022- | Jun 30, 2022) | ||||||||||||||||||||
2022) | |||||||||||||||||||||||
19/12/2018 | Meeting on | ||||||||||||||||||||||
Jun 30, 2022) | |||||||||||||||||||||||
30/04/2019 | |||||||||||||||||||||||
1. | Investment in raw | 100.00 | 100.00 | 260.00 | 29.02 | 241.32 | 18.68 | ||||||||||||||||
material extraction plant | |||||||||||||||||||||||
and world-class research | |||||||||||||||||||||||
laboratory | |||||||||||||||||||||||
2. Development of the | 200.00 | 200.00 | - | - | - | - | |||||||||||||||||
Company's new brand | |||||||||||||||||||||||
3. Repayment of loans to | 50.00 | 50.00 | 46.89 | - | 46.89 | - | |||||||||||||||||
financial institutions | |||||||||||||||||||||||
4. Working capital for | 637.34 | 368.34 | 221.45 | - | 221.45 | - | |||||||||||||||||
business operation | |||||||||||||||||||||||
5. Expansion of production | - | 120.90 | 120.90 | - | 120.90 | - | |||||||||||||||||
capacity for dietary | |||||||||||||||||||||||
supplement products, | |||||||||||||||||||||||
introduction of new | |||||||||||||||||||||||
product packages, and | |||||||||||||||||||||||
warehouse building | |||||||||||||||||||||||
(related to existing | |||||||||||||||||||||||
business as disclosed in | |||||||||||||||||||||||
the Registration Statement | |||||||||||||||||||||||
for offer for sale of | |||||||||||||||||||||||
securities and draft | |||||||||||||||||||||||
prospectus) | |||||||||||||||||||||||
Page 1 | 2
Purposes of use | Amount | Resolution of | Resolution of | Amount | Accumulated | Balance | ||||||||||||
(Unit: Baht million) | earmarked | the Board of | the 2019 | used during | amount used | remaining | ||||||||||||
Directors No. | Annual | period | (Jun 15, 2018- | (Jun 30, | ||||||||||||||
8/2018 on | General | (Jan 1, 2022- | Jun 30, 2022) | |||||||||||||||
2022) | ||||||||||||||||||
19/12/2018 | Meeting on | |||||||||||||||||
Jun 30, 2022) | ||||||||||||||||||
30/04/2019 | ||||||||||||||||||
6. Lending to a subsidiary | - | 148.00 | 148.00 | - | 148.00 | - | ||||||||||||
for investment and | ||||||||||||||||||
expansion of contracted | ||||||||||||||||||
manufacturing of | ||||||||||||||||||
cosmetics- PCCA | ||||||||||||||||||
Laboratory Co., Ltd. (new | ||||||||||||||||||
business) | ||||||||||||||||||
7. Use to repay loans from | - | - | 150.00 | - | 150.00 | - | ||||||||||||
financial institution Which | ||||||||||||||||||
is intended for investment | ||||||||||||||||||
in PCCA (New Business) | ||||||||||||||||||
8.Use investment in | - | - | 40.00 | - | 40.00 | - | ||||||||||||
subsidiaries that operate | ||||||||||||||||||
direct sale business (New | ||||||||||||||||||
business) | ||||||||||||||||||
Total | 987.24 | 987.24 | 987.24 | 29.02 | 968.56 | 18.68 | ||||||||||||
Please be informed accordingly.
Yours sincerely,
Miss Suwarin Konthong
Director
Page 2 | 2